Peptides for Face and Skin 2026: GHK-Cu, Argireline and Cosmetic Research

In short

Peptides for the face are short chains of amino acids that are investigated in the dermatological and cosmetic research literature for their modulatory effects on collagen, elastin, pigmentation, mimic wrinkles and cellular regeneration. They are not universal “anti-ageing magic bullets” but rather a family of molecules with distinct mechanisms and varying levels of scientific evidence.

In research practice in 2026, four peptides dominate:

• GHK-Cu (Copper Tripeptide-1), the oldest and best-documented copper peptide, modulating over 4,000 genes, stimulating collagen and ECM remodelling. Discovered by Loren Pickart in 1973.
• Argireline (Acetyl Hexapeptide-8), a “botox-like” hexapeptide inhibiting the SNARE complex and reducing the activity of mimic muscles. Developed by Lipotec Barcelona in 2002.
• Snap-8 (Acetyl Octapeptide-3), an extended version of argireline with two additional amino acids and stronger inhibition of muscle contraction.
• Epithalon (AEDG tetrapeptide), Khavinson’s peptide, indirectly related to the skin via telomerase activation and longevity pathways.

Key distinctions in one sentence: GHK-Cu remodels the matrix of the skin (collagen, elastin, glycosaminoglycans); argireline and Snap-8 attenuate mimic wrinkles via SNARE inhibition; epithalon is investigated as a longevity peptide with indirect effects on skin ageing.

Details, mechanisms, dosing in studies and a decision tree follow.

Quick comparison table

The table sets the four peptides side by side on the properties that decide which one a model needs: GHK-Cu is a 402 Da copper tripeptide from 1973 that modulates over 4,000 genes, argireline and Snap-8 are SNARE inhibitors from 2002 and 2008, and epithalon is a longevity tetrapeptide. The first three carry INCI names as cosmetic ingredients, epithalon has no EU registration.

1. What “peptides for the face” are, and what they are not

They are cosmetic and research peptides applied mostly topically, not injectable facial treatments and not a substitute for botulinum toxin or fillers. The category covers matrix modulators such as GHK-Cu and neuro-inhibitory peptides such as argireline and Snap-8. They are not oral supplements, not hormones and not approved medicines for the skin.

The term “peptides for the face” is a popular marketing expression covering a very heterogeneous group of molecules. In the dermatological research literature, the more precise designation is cosmetic peptides (Eng. cosmeceutical peptides), short chains of amino acids (typically 3–15 AA) applied topically or, in experimental models, subcutaneously to modulate processes within the skin.

Cosmetic peptides are, in the research literature (Errante 2020, Pai 2017), divided into four principal categories:

1. Signalling peptides (matrix modulators). They stimulate fibroblasts to synthesise collagen, elastin and glycosaminoglycans. Prototype: GHK-Cu, palmitoyl pentapeptides (Matrixyl), palmitoyl tripeptides.

2. Neurotransmitter-inhibitory peptides. They mimic the local effect of botulinum toxin by blocking the SNARE complex, the molecular machine responsible for acetylcholine release from nerve terminals into muscle. Prototype: Argireline (Acetyl Hexapeptide-8) and Snap-8.

3. Carrier peptides. They transport trace elements (chiefly copper, manganese) into cells. Prototype: again GHK-Cu, which overlaps categories 1 and 3.

4. Enzyme-inhibitory peptides. They block enzymes that degrade collagen (matrix metalloproteinases, MMPs). Prototype: soy-derived peptides, rice peptides.

What peptides for the skin are not:

• They are not botulinum toxin. Argireline has no enzymatic activity like Botox®; it merely blocks the SNARE complex through competition.
• They are not a medicine. In the EU they are registered as cosmetic ingredients (Regulation 1223/2009), not as medicines.
• They are not collagen supplements. Collagen peptides from porcine skin (hydrolysed collagen) in powder form are an entirely different class of molecule, section 8 discusses this distinction.
• They are not universal. Each peptide occupies a narrow, specific mechanistic niche; none “does everything”.

For the research community working with research-grade (RUO) peptides outside finished cosmetic formulations, this taxonomy is important, it enables selection of the appropriate molecule for a specific experimental model (fibroblast culture, ex vivo human skin, animal model, mimic-wrinkle assessment).

2. GHK-Cu, the oldest and most researched copper peptide

GHK-Cu is a copper tripeptide discovered by Loren Pickart in 1973 and the best documented cosmetic peptide in the dermatological literature, with over 200 peer reviewed studies. Transcriptomic analysis (Pickart 2014) showed it modulates roughly 4,192 human genes, about 31 percent of the protein coding genome, and it raised collagen I and III synthesis by 70 percent in Maquart 1988.

Discovery and history

GHK-Cu (Copper Tripeptide-1) is unquestionably the best-documented cosmetic peptide in the entire dermatological literature. It was discovered by the American biochemist Loren Pickart in 1973 while studying differences between the plasma of young and older adults. He determined that plasma from young individuals stimulated the growth of hepatic cells and tissue regeneration, whereas plasma from older individuals progressively lost this capacity. The active constituent was identified as the tripeptide Glycyl-Histidyl-Lysine (Gly-His-Lys) bound to a Cu²⁺ ion.

According to Pickart’s measurements, the plasma level of GHK-Cu declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60 (Pickart 2015, PubMed 26236730). This decline correlates with the age-related loss of regenerative capacity of the skin.

Structure and INCI

• Sequence: Gly-His-Lys + Cu²⁺
• Molecular mass: 402 Da
• CAS: 89030-95-5
• INCI (EU): Copper Tripeptide-1 (registered in the EU Commission CosIng database)
• Appearance: intensely blue lyophilised powder (Cu²⁺ complex)

Mechanism, why it is so broad

According to transcriptomic analysis (Pickart 2014), GHK-Cu modulates the expression of approximately 4,192 human genes, approximately 31 % of the entire human protein-coding genome. This is an unprecedentedly broad effect for a single molecule and explains why GHK-Cu functions in so many diverse dermatological models.

Key mechanisms relevant to the skin:

• Stimulation of the synthesis of collagen I and III in fibroblasts (+70 % in Maquart 1988)
• Stimulation of elastin and glycosaminoglycans (hyaluronan, decorin, dermatan sulphate)
• Activation of lysyl oxidase, the copper-dependent enzyme that mediates cross-linking of collagen fibres
• Antioxidant protection via SOD1 (Cu/Zn superoxide dismutase)
• Anti-glycation effect, protecting collagen against glycation and the formation of AGEs (Advanced Glycation End-products)
• Modulation of DNA repair genes (BER, NER, HR pathways)

Investigated dermatological applications

In the published literature, GHK-Cu has been investigated in the following areas:

• Anti-ageing dermatology, reduction of wrinkles, increased elasticity, thickening of the dermis
• Cutaneous wound healing, including diabetic ulcers (Mazurowski 1995)
• Skin barrier function, repair of damaged epidermis
• Photoageing, protection against UV damage
• Hyperpigmentation, modulation of melanogenesis
• Hair follicles, extension of the anagen phase, hair thickness
• Post-procedural regeneration, healing after laser and peeling procedures

A detailed technical profile of the molecule, dosing protocols in studies and reconstitution are presented in the product guide GHK-Cu on Molequa.

3. Argireline, the hexapeptide with a “botox-like” mechanism

Argireline (Acetyl Hexapeptide-8) is a hexapeptide developed in Barcelona in 2002 to mimic the peripheral action of botulinum toxin without using a neurotoxin. It competes with SNAP-25 in the SNARE complex and weakens acetylcholine release. The original study (Blanes-Mira 2002, Int J Cosmet Sci) recorded roughly 30 percent wrinkle reduction at 10 percent topical concentration over 30 days.

Discovery and origin

Argireline (trademark of Lipotec, now Lubrizol) was developed in 2002 in Barcelona by the research team of Blanes-Mira and colleagues. Its development was targeted, the objective was to design a synthetic peptide that would mimic the peripheral mechanism of botulinum toxin without using a neurotoxin, while providing topical availability for cosmetic applications.

Landmark publication: Blanes-Mira C. et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci 24(5):303–310. PubMed 18494895

Structure and INCI

• Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂
• Molecular mass: 888.9 Da
• CAS: 616204-22-9
• INCI (EU): Acetyl Hexapeptide-8 (formerly Acetyl Hexapeptide-3, renamed)
• Appearance: white to off-white lyophilised powder

Mechanism, SNARE inhibition

Argireline shares its N-terminal sequence with SNAP-25, a key protein in the so-called SNARE complex (Soluble N-ethylmaleimide-sensitive-factor Attachment protein REceptor). The SNARE complex is the molecular machine that ensures fusion of acetylcholine-containing vesicles with the presynaptic membrane at the neuromuscular junction. Without the SNARE complex → no acetylcholine → no muscle contraction.

Botulinum toxin A (Botox®) permanently cleaves this complex enzymatically. Argireline blocks it by competition, occupying the site of SNAP-25 and preventing full assembly of a functional SNARE complex. Differences:

• Botox®, an enzymatic protease, permanent effect 3–4 months, applied by injection
• Argireline, reversible competition, acute topical effect, applied in creams/serums

The outcome upon topical application in research models: reduced amplitude of mimic contractions in the upper third of the face (forehead, glabella, eye corners). With repeated use, this leads to reduction of dynamic (mimic) wrinkles.

Clinical studies and limitations

• Blanes-Mira 2002, the original study, 10 % Argireline in a topical emulsion, wrinkle reduction of ~30 % over 30 days
• Wang 2013, comparative study, Argireline versus placebo, statistically significant improvement
• Pai 2017 (PubMed 29204382), review article ranking Argireline among the “most studied” cosmetic peptides

Limitations of the evidence:

• The majority of studies are industry-sponsored (Lipotec)
• Topical permeability of the hexapeptide into the dermal layer is limited, part of the effect is likely mediated by stratum corneum effects
• The effect is mild to moderate and does not reach the intensity of Botox

A detailed profile of the molecule, dosing in research models and stability in solution are provided in the Argireline guide on Molequa.

4. Snap-8, the octapeptide, a stronger version of argireline

Snap-8 (Acetyl Octapeptide-3) is the 2008 octapeptide extension of argireline, two amino acids longer at 1,093 Da and designed for stronger SNARE inhibition. Head to head cosmetic comparisons typically show 20 to 30 percent greater reduction of mimic wrinkles at the same concentration, although independent peer reviewed data on Snap-8 remain far thinner than for argireline.

Development and origin

Snap-8 (Acetyl Octapeptide-3) is an extended version of argireline, containing the same 6 amino acids as argireline plus two additional amino acids at the C-terminus (Ser-Ser). It was developed as a new generation SNARE-inhibitory peptide with the aim of increasing binding strength and topical efficacy.

Snap-8 may be considered “argireline 2.0”, the same mechanism with stronger binding to SNAP-25.

Structure and INCI

• Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ser-Ser-NH₂ (8 AA)
• Molecular mass: 1,093 Da
• INCI (EU): Acetyl Octapeptide-3
• Appearance: white lyophilised powder

Mechanism and difference from argireline

Snap-8 employs the same SNARE inhibition as argireline, but the extended C-terminal sequence (Arg-Arg-Ser-Ser) provides:

• Stronger affinity for the SNAP-25 binding site
• Presumed higher topical efficacy in comparative in vitro models
• A similar safety profile (no observed systemic effects at topical concentrations of 5–10 %)

In the research literature, Snap-8 is frequently compared with argireline in head-to-head cosmetic studies, in which Snap-8 typically exhibits a 20–30 % greater reduction of mimic wrinkles at comparable concentration. Direct independent peer-reviewed studies remain limited, however.

When Snap-8 is selected

In research dermatological protocols, Snap-8 is preferred over argireline when:

• The objective is maximum neuro-inhibitory potency in a topical model
• It is combined with GHK-Cu for a comprehensive effect (matrix + neuro components)
• A newer molecule with potentially stronger affinity is sought

Details are provided in the Snap-8 guide on Molequa.

5. Epithalon and longevity cosmetics, indirect effect on the skin

Epithalon is a four amino acid bioregulator from the Khavinson school, studied for telomerase activation rather than for any direct effect on the skin. Any relevance to appearance is indirect, through systemic ageing pathways. It has no INCI name and no EU cosmetic registration, and in research literature it is used subcutaneously rather than topically.

Origin and the Khavinson school

Epithalon (also epitalon, Epithalone) is a tetrapeptide Ala-Glu-Asp-Gly (AEDG) developed by the Soviet/Russian gerontologist Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in the 1990s. It does not belong to the classical “skincare” category, it is a longevity peptide investigated for its systemic anti-ageing effect.

Why Epithalon is relevant to the skin

Epithalon does not directly stimulate collagen nor does it block mimic muscles. Its relevance to the skin is indirect and arises from three angles:

1. Telomerase activation. In published experiments (Khavinson et al. 2003), Epithalon increases the activity of telomerase, the enzyme that extends telomeres (the terminal segments of chromosomes). Shortening of telomeres is one of the principal molecular markers of ageing. Extension of telomeres in dividing cells (including cutaneous fibroblasts) may delay cellular senescence.

2. Systemic longevity effect. In Russian gerontological studies (often of contested methodology), Epithalon has been associated with systemic extension of lifespan in experimental animals. Should this effect be replicated in a human dermatological matrix, it would imply slower skin ageing as part of slower organismal ageing.

3. Melatonin normalisation via the epiphysis. Epithalon was originally isolated from the epiphysis (pineal gland). It normalises the circadian rhythm and melatonin production, which may indirectly benefit cutaneous regenerative processes during sleep.

Limitations and cautions

• Clinical evidence is limited, most publications derive from the Khavinson school, whose methodology is frequently criticised by the Western community
• It is not registered in the EU as a cosmetic ingredient, it is not used in cosmetic formulations
• Application in research is typically subcutaneous (SC), not topical
• Direct dermatological studies are lacking, the anti-ageing effect on the skin is theoretical, extrapolated from the systemic effect

Details on Epithalon, its mechanism and stability are provided in the Epithalon guide on Molequa.

6. Comparison table: GHK-Cu vs Argireline vs Snap-8 vs Epithalon

The table separates the two mechanisms that matter: GHK-Cu works on the matrix and therefore on static, collagen dependent wrinkles, while argireline and Snap-8 act at the neuromuscular junction and therefore on dynamic, mimic wrinkles. Epithalon belongs to neither group. That is why GHK-Cu is usually combined with argireline or Snap-8 rather than compared against them.

This is a reference table for rapid decision-making on peptide selection according to the research question.

Interpretation:

• For static wrinkles and loss of elasticity (related to loss of collagen), GHK-Cu is the clear choice
• For dynamic (mimic) wrinkles, Argireline or Snap-8 are more appropriate, with Snap-8 being the stronger option
• For comprehensive anti-ageing protocols, a combination of a matrix modulator (GHK-Cu) with a neuro-inhibitor (Snap-8) is meaningful
• Epithalon occupies a distinct category, not a classical “skincare” peptide but a longevity molecule with indirect cutaneous effects

7. How peptides for the skin differ from collagen supplements

Collagen supplements are taken orally in grams as building material and act systemically and non-specifically; cosmetic peptides are applied topically in micrograms to milligrams and act as direct signals in the skin. Collagen studies typically need 8 to 12 weeks, whereas peptide effects range from hours for the neuro-inhibitory molecules to several weeks for GHK-Cu.

This is a frequent source of confusion within the community. Collagen supplements (hydrolysed collagen, collagen peptides in powder form, collagen in gummies) are an entirely different class of molecule from cosmetic peptides such as GHK-Cu or argireline.

Collagen supplements (kompava.sk, dm, others)

What they are:

• Hydrolysed collagen (usually porcine or bovine, sometimes fish)
• Chain length: 2–30 amino acids (di-, tri-, tetrapeptides)
• Composition: high proportion of glycine, proline and hydroxyproline
• Route of administration: oral (in powder, liquid form, gummies)

Mechanism:

• Collagen is degraded in the stomach and intestine to dipeptides and amino acids
• These are absorbed and enter the amino acid pool of the body
• Fibroblasts may utilise them as building material for new collagen synthesis
• Certain dipeptides (Pro-Hyp, Hyp-Gly) may also exert a signalling effect via the PPAR-γ pathway

Effect:

• Mild improvement of skin hydration and elasticity (meta-analyses 2019–2023)
• The effect is systemic and non-specific, collagen distributes to all tissues, not solely the face
• Requires long-term use (12+ weeks) at doses of 5–10 g daily

Cosmetic peptides (GHK-Cu, Argireline, Snap-8)

What they are:

• Specifically designed short peptides (3–8 AA) with defined sequences
• A specific target mechanism (matrix, SNARE, telomerase)
• Route of administration: topical (creams, serums) or subcutaneous (research models)

Mechanism:

• Direct signalling, the peptide interacts with a specific pathway (VEGFR2, SNAP-25, telomerase)
• Active per-cell effect, not “building material”
• Local action, concentrated at the site of application

Effect:

• Specific and mechanistically targeted
• Measurable within hours to weeks (depending on mechanism)
• Lower doses required (micrograms to milligrams versus grams for collagen)

Summary

Are these two approaches competitive or complementary? In the research literature there is no evidence that they mutually exclude each other, collagen supplies building amino acids, while GHK-Cu stimulates fibroblasts to utilise them more efficiently. In practical terms these are distinct categories with distinct regulatory frameworks, and direct comparison of “which is better” is not scientifically meaningful, the target mechanisms are too dissimilar.

8. Clinical studies 2015–2024, what the modern literature shows

Between 2015 and 2024 the literature moved from single ingredient claims toward mechanism and formulation: GHK-Cu gained transcriptomic and wound healing evidence, argireline accumulated roughly 30 studies over twenty years, and Snap-8 still has about ten. The volume of evidence is uneven, which is the main reason GHK-Cu remains the reference peptide in dermatological research.

GHK-Cu

• Pickart L., Vasquez-Soltero JM., Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015:648108. PubMed 26236730, comprehensive review of mechanisms and clinical applications, 4,000+ genes, transcriptomic profile
• Pickart L. (2008). The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 19(8):969–988. PubMed 18644225, fundamental review article
• Pickart L., Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 19(7):1987, updated review

Argireline

• Blanes-Mira C. et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci 24(5):303–310. PubMed 18494895, original publication of the molecule
• Pai VV., Bhandari P., Shukla P. (2017). Cosmeceutical peptides. Indian Dermatol Online J 8(6):412–421. PubMed 29204382, review classification of cosmetic peptides with argireline as one of the principal examples

Comprehensive view of cosmetic peptides

• Errante F. et al. (2020). Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem 8:572923. PubMed 33195059, modern review of the categories of cosmetic peptides, their mechanisms and the sustainability of synthesis

Trends 2020–2024

• Growing interest in combination protocols, matrix + neuro (GHK-Cu + Snap-8)
• Extension into post-procedural medicine, GHK-Cu as adjunctive therapy after fractional lasers and chemical peels
• New generations of SNARE inhibitors, Leuphasyl (pentapeptide-18), SYN-AKE, with the aim of a stronger effect and improved topical permeability
• Longevity directions, Epithalon, Vialox and further tetrapeptides with non-specific anti-ageing claims (the evidence base remains limited)

9. Reconstitution and topical versus subcutaneous application (research models)

In research models cosmetic peptides are applied topically, not injected into the face. GHK-Cu is used at 0.05 to 0.1 percent, argireline and Snap-8 at 5 to 10 percent. Subcutaneous use appears only in animal models, GHK-Cu at 1 to 10 mg/kg and epithalon at 5 to 10 mg. GHK-Cu must be protected from light, because the copper ion degrades under UV.

Cosmetic peptides are typically not injected into the face

This is a key misunderstanding in the lay community. In research models, topical application is used most frequently for cosmetic peptides, because:

• The target is the skin, topical application delivers the peptide directly to the site where it is needed
• Subcutaneous injection into the face is reserved for clinical procedures (hyaluronic acid, botulinum toxin), not for cosmetic peptides
• The safety of topical application has been verified in dozens of clinical studies

Topical application, research parameters

In research dermatological models (clinical, ex vivo skin, 3D skin models):

Systemic (SC) application, only in research animal models

In published animal studies, GHK-Cu is also used subcutaneously at doses of 1–10 mg/kg daily for 2–6 weeks (models of wound healing and systemic regeneration). Epithalon is administered SC in research longevity literature at doses of 5–10 mg in cyclical protocols.

For argireline and Snap-8, subcutaneous application is atypical, their mechanism is peripheral (neuromuscular junction), and the topical route is sufficient.

Reconstitution, basic rules

In research practice (RUO peptides in lyophilised form):

• Bacteriostatic water (0.9 % benzyl alcohol) is the standard solvent for injectable models
• Sterile distilled water for topical formulations
• Slow addition along the wall of the vial, never directly onto the lyophilisate
• Swirling motion, never shaking (peptides are sensitive to mechanical stress)
• Storage in the refrigerator at 2–8 °C after reconstitution, protected from light

For GHK-Cu, protection from light is critical, the Cu²⁺ ion is sensitive to redox degradation upon UV exposure. A detailed reconstitution protocol is provided in a dedicated guide: How to Reconstitute Lyophilisate.

10. Frequently asked questions about peptides for the face

Which peptide for the skin is most effective according to scientific studies?

Based on the volume of published evidence, the best-documented peptide is GHK-Cu, over 200 peer-reviewed studies over 50 years, transcriptomic validation (4,000+ genes), foundational mechanistic studies (Maquart 1988) and clinical studies in wound healing. For the specific effect on mimic wrinkles, the best-studied peptide is argireline (Blanes-Mira 2002 and subsequent works). “Most effective” therefore depends on the target indication, for matrix and collagen, GHK-Cu; for dynamic wrinkles, argireline or Snap-8.

What is the difference between GHK-Cu and argireline?

GHK-Cu is a regenerative matrix modulator, it stimulates fibroblasts to synthesise collagen, elastin and glycosaminoglycans, modulates ~4,000 genes and delivers copper as an essential trace element. Argireline is an inhibitor of the SNARE complex, it blocks acetylcholine release at the neuromuscular junction, thereby reducing the activity of mimic muscles. GHK-Cu targets long-term tissue remodelling (static wrinkles, elasticity); argireline delivers an acute muscle-relaxant effect (mimic wrinkles). In research protocols the two are combined for a comprehensive effect.

Do cosmetic peptides actually work?

Yes, but with qualification. Peer-reviewed studies demonstrate measurable effects in research dermatological models: GHK-Cu +70 % collagen synthesis in fibroblast cultures (Maquart 1988); argireline ~30 % reduction of wrinkle amplitude over 30 days of topical application of a 10 % formulation (Blanes-Mira 2002). The effect is mild to moderate and does not reach the intensity of professional procedures (Botox®, hyaluronic acid, laser). In research terms, cosmetic peptides constitute a validated tool with defined mechanisms, not a “miraculous” product.

How long does it take for peptide effects on the skin to appear?

This depends on the mechanism:

• Argireline / Snap-8 (SNARE inhibition), measurable effect after 4–8 weeks of topical application twice daily
• GHK-Cu (matrix modulation), measurable effect after 8–12 weeks, with full collagen-remodelling effect requiring 3–6 months (biological turnover of collagen)
• Epithalon (longevity), no direct dermatological studies; the systemic longevity effect is evaluated over months to years

For research assessment of wrinkles (photodocumentation, elasticity measurement, 3D analysis), 12-week protocols are standard.

Are peptides for the skin safe?

In topical application, cosmetic peptides (GHK-Cu, argireline, Snap-8) are very well tolerated, clinical dermatological studies have recorded no significant adverse effects at the recommended concentrations (5–10 % for argireline/Snap-8; 0.05–0.1 % for GHK-Cu). Rarely, local irritation or allergic reactions occur in sensitive individuals. At the research level (RUO), peptides are sold exclusively for laboratory scientific research and are not intended for human use outside approved clinical research protocols.

How should peptides for the skin be stored and used correctly in studies?

Lyophilised powder:

• −20 °C for long-term storage (2–3 years for most peptides)
• 2–8 °C for short-term storage (12–18 months)
• Protected from light and moisture (GHK-Cu is particularly light-sensitive owing to Cu²⁺)

After reconstitution:

• 2–8 °C, protected from light
• Argireline / Snap-8: stable for 14–28 days
• GHK-Cu: stable for 30 days under strictly light-protected storage (the blue colour indicates an intact complex)
• Do not freeze after reconstitution (crystallisation may disrupt the complex)

Where can research cosmetic peptides be obtained in the EU?

The full range of peptides for sale is available in the Molequa® catalogue, HPLC/MS tested, with a certificate of analysis for every batch and EU delivery.

Research cosmetic peptides (GHK-Cu, Argireline, Snap-8, Epithalon) for laboratory scientific research in the EU are offered by Molequa® with FedEx delivery within 1 to 3 business days across Slovakia, the Czech Republic and the EU. All peptides are supplied in lyophilised form with a certificate of analysis (COA), HPLC purity ≥ 99 %, MS confirmation of molecular identity and LAL endotoxin testing. Molequa® products are sold exclusively for laboratory scientific research (RUO), they are not a medicine, cosmetic product for the end consumer or dietary supplement.

Conclusion, decision tree for the researcher

For readers who are researchers or dermatologists selecting a peptide for a specific model, the following simplified decision tree is provided:

Objective = static wrinkles, loss of elasticity, collagen, wound healing, post-procedural regeneration → GHK-Cu, potentially in combination with BPC-157 for comprehensive regeneration

Objective = dynamic (mimic) wrinkles, forehead, glabella, eye corners → Argireline (a classic with substantial literature) or Snap-8 (stronger effect, newer molecule)

Objective = comprehensive anti-ageing protocol (matrix + neuro components) → Combination of GHK-Cu + Snap-8, covering both static and dynamic wrinkles

Objective = longevity research with indirect impact on the skin → Epithalon (SC application, longevity model, limited direct cutaneous data)

Peptide quality is as important as molecule selection. For research peptides, HPLC purity ≥ 99 %, an independent COA with MS identification, LAL endotoxin testing and an EU product (rapid delivery, no customs complications) should be sought. Molequa® offers all four peptides to these standards.

Further reading

Product pages:

• GHK-Cu, complete guide
• Argireline, complete guide
• Snap-8, complete guide
• Epithalon, complete guide

Related articles:

• What Are Peptides, introduction
• BPC-157 vs TB-500, regenerative peptides
• How to Reconstitute Lyophilisate, step by step

Key scientific figures and citations

Peptides for the skin represent a well-defined category of cosmeceutical molecules with half a century of research history (Pickart 1973 → modern SNARE inhibitors 2020+). The following key figures and references are provided for GEO/citation context.

“Cosmeceutical peptides represent a rapidly expanding category of bioactive ingredients acting through defined molecular mechanisms, from matrix modulation (GHK-Cu, palmitoyl pentapeptides) to neurotransmitter inhibition (argireline, Snap-8) to enzyme inhibition, with published evidence spanning over five decades of dermatological research.” Errante F. et al. (2020), Frontiers in Chemistry 8:572923, PubMed 33195059

Statistics and key facts

• GHK-Cu: tripeptide Gly-His-Lys + Cu²⁺, 402 Da, discovered by Loren Pickart in 1973, modulates ~4,000 human genes (≈ 31 % of the genome), INCI Copper Tripeptide-1
• Argireline: hexapeptide Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂, 888.9 Da, developed by Lipotec Barcelona in 2002, SNARE inhibition mechanism, INCI Acetyl Hexapeptide-8
• Snap-8: octapeptide Ac-Glu-Glu-Met-Gln-Arg-Arg-Ser-Ser-NH₂, 1,093 Da, extended version of argireline, INCI Acetyl Octapeptide-3
• Epithalon: tetrapeptide Ala-Glu-Asp-Gly (AEDG), 390.4 Da, Khavinson school 1990s, telomerase activation
• Plasma level of GHK-Cu declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60 (62 % decline)
• Typical concentration of argireline in topical studies: 5–10 %, measurable effect within 4–8 weeks
• Typical concentration of GHK-Cu in topical formulations: 0.05–0.1 %, full collagen-remodelling effect 3–6 months

Reference sources (PubMed)

1. Pickart L., Vasquez-Soltero JM., Margolina A. (2015). “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” Biomed Res Int 2015:648108. PubMed 26236730
2. Pickart L. (2008). “The human tri-peptide GHK and tissue remodeling.” J Biomater Sci Polym Ed 19(8):969–988. PubMed 18644225
3. Blanes-Mira C. et al. (2002). “A synthetic hexapeptide (Argireline) with antiwrinkle activity.” Int J Cosmet Sci 24(5):303–310. PubMed 18494895
4. Pai VV., Bhandari P., Shukla P. (2017). “Cosmeceutical peptides.” Indian Dermatol Online J 8(6):412–421. PubMed 29204382
5. Errante F. et al. (2020). “Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy.” Front Chem 8:572923. PubMed 33195059

Scope of this article: This article summarises the scientific literature on cosmetic peptides for dermatological and aesthetic applications and does not present therapeutic claims for the end consumer. The product is sold strictly for laboratory scientific research (RUO).

Legal notice

GHK-Cu, Argireline, Snap-8, Epithalon and all Molequa® products are intended exclusively for research and scientific purposes (RUO, Research Use Only). They are not a medicine, dietary supplement, cosmetic product for the end consumer or foodstuff. They are not intended for human or animal consumption outside approved clinical research protocols. Sale is restricted to qualified researchers, academic institutions and laboratories. Before any handling, the relevant scientific literature should be consulted and applicable legislation in the user’s jurisdiction should be observed (in the EU, notably Regulation 1223/2009 for cosmetics and REACH for chemical substances).

Author: Molequa® Research Team Publication date: July 2026 Last update: July 2026 Reading time: ~12 min